Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS

[1]  H. Mikaeili,et al.  Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial , 2021, Thrombosis Research.

[2]  Marcelo A. Falappa,et al.  Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial , 2021, BMJ.

[3]  J. Halperin,et al.  Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. , 2021, JAMA internal medicine.

[4]  M. Cushman,et al.  Heparin for Moderately Ill Patients with Covid-19 , 2021, medRxiv.

[5]  S. Khan.  The Central Role of PAI-1 in COVID-19: Thrombosis and beyond , 2021, American journal of respiratory cell and molecular biology.

[6]  D. Angus,et al.  Therapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 , 2021, medRxiv.

[7]  D. Leaf,et al.  Tissue Plasminogen Activator in Critically Ill Adults with COVID-19 , 2021, Annals of the American Thoracic Society.

[8]  Xiaochun Ma,et al.  Understanding COVID-19-associated coagulopathy: From PIC to SIC or DIC , 2021, Journal of Intensive Medicine.

[9]  J. Marshall,et al.  Therapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report , 2021, medRxiv.

[10]  E. Moore,et al.  Fibrinolysis Shutdown in COVID-19: Clinical Manifestations, Molecular Mechanisms, and Therapeutic Implications , 2021, Journal of the American College of Surgeons.

[11]  G. Buitrago Weiland,et al.  Radiologic aspects of COVID-19 pneumonia: Outcomes and thoracic complications , 2021, Radiología (English Edition).

[12]  R. Schermuly,et al.  Recombinant tissue plasminogen activator treatment for COVID-19 associated ARDS and acute cor pulmonale , 2020, International Journal of Infectious Diseases.

[13]  G. B. Weiland,et al.  Radiologic aspects of COVID-19 pneumonia: outcomes and thoracic complications. , 2020, Radiologia.

[14]  J. Raffetto,et al.  Sulodexide in the treatment of patients with early stages of COVID-19: a randomised controlled trial , 2020, medRxiv.

[15]  Hailin Zhao,et al.  Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications , 2020, Inflammation.

[16]  T. Hirano,et al.  How COVID-19 induces cytokine storm with high mortality , 2020, Inflammation and regeneration.

[17]  L. Csiba,et al.  Stroke as a Potential Complication of COVID-19-Associated Coagulopathy: A Narrative and Systematic Review of the Literature , 2020, Journal of clinical medicine.

[18]  G. Lippi,et al.  Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19) , 2020, Seminars in Thrombosis and Hemostasis.

[19]  T. Ortel,et al.  ISTH DIC subcommittee communication on anticoagulation in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[20]  F. Drago,et al.  The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review , 2020, Frontiers in Pharmacology.

[21]  Arthur S Slutsky,et al.  Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial , 2020, Clinical trials.

[22]  W. Aronow,et al.  Management of Thrombotic Complications in COVID-19: An Update , 2020, Drugs.

[23]  I. Berindan‐Neagoe,et al.  A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19 , 2020, Archives of Medical Research.

[24]  B. Singer,et al.  Pathogenesis of COVID-19-induced ARDS: implications for an ageing population , 2020, European Respiratory Journal.

[25]  I. Haznedaroglu,et al.  Three critical clinicobiological phases of the human SARS-associated coronavirus infections. , 2020, European review for medical and pharmacological sciences.

[26]  Z. Memish,et al.  Thrombolysis in severe COVID-19 pneumonia with massive pulmonary embolism , 2020, The American Journal of Emergency Medicine.

[27]  N. Laura,et al.  Interleukin-6-based mortality risk model for hospitalised COVID-19 patients , 2020, Journal of Allergy and Clinical Immunology.

[28]  S. Warach,et al.  Stroke Thrombolysis With Tenecteplase to Reduce Emergency Department Spread of Coronavirus Disease 2019 and Shortages of Alteplase. , 2020, JAMA Neurology.

[29]  C. Righy,et al.  Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19 , 2020, Blood.

[30]  M. Chung,et al.  New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis , 2020, BMC Medicine.

[31]  A. Goyal,et al.  Successful use of tPA for thrombolysis in COVID related ARDS: a case series , 2020, Journal of Thrombosis and Thrombolysis.

[32]  M. Levi,et al.  Thrombosis and coagulopathy in COVID‐19: An illustrated review , 2020, Research and Practice in Thrombosis and Haemostasis.

[33]  D. Kell,et al.  Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes , 2020, International journal of molecular sciences.

[34]  R. Fumagalli,et al.  Role of von Willebrand Factor and ADAMTS-13 in the Pathogenesis of Thrombi in SARS-CoV-2 Infection: Time to Rethink , 2020, Thrombosis and Haemostasis.

[35]  P. Pelosi,et al.  Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2 , 2020, Expert review of respiratory medicine.

[36]  D. Roccatello,et al.  Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients , 2020, Internal and Emergency Medicine.

[37]  A. White,et al.  The Role of Anticoagulation in COVID-19-Induced Hypercoagulability , 2020, Current Cardiology Reports.

[38]  P. Myles,et al.  Fibrinolysis and COVID‐19: A plasmin paradox , 2020, Journal of Thrombosis and Haemostasis.

[39]  C. Cañas,et al.  Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19 , 2020, Journal of Thrombosis and Thrombolysis.

[40]  A. Komnos,et al.  Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report , 2020, International Journal of Infectious Diseases.

[41]  A. Sauaia,et al.  Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial , 2020, Research and Practice in Thrombosis and Haemostasis.

[42]  T. Uyeki,et al.  Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States , 2020, Emerging infectious diseases.

[43]  G. Mahé,et al.  Can Ticagrelor be used to prevent sepsis-induced coagulopathy in COVID-19? , 2020, Clinical Immunology.

[44]  D. Talmor,et al.  Rescue therapy for severe COVID-19–associated acute respiratory distress syndrome with tissue plasminogen activator: A case series , 2020, The journal of trauma and acute care surgery.

[45]  H. Poor,et al.  COVID‐19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis , 2020, Clinical and translational medicine.

[46]  P. Emery,et al.  Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia , 2020, The Lancet Rheumatology.

[47]  F. Sariali̇oğlu,et al.  Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy , 2020, Journal of Thrombosis and Thrombolysis.

[48]  J. Connors,et al.  COVID-19 and its implications for thrombosis and anticoagulation , 2020, Blood.

[49]  C. Whyte,et al.  Fibrinolytic abnormalities in acute respiratory distress syndrome (ARDS) and versatility of thrombolytic drugs to treat COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[50]  D. Talmor,et al.  Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis , 2020, World Journal of Emergency Surgery.

[51]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[52]  H. Ogawa,et al.  Potential of heparin and nafamostat combination therapy for COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[53]  E. Grandone,et al.  Pulmonary thrombosis in 2019‐nCoV pneumonia? , 2020, Journal of Thrombosis and Haemostasis.

[54]  M. Aschner,et al.  Zinc and respiratory tract infections: Perspectives for COVID-19 (Review) , 2020, International journal of molecular medicine.

[55]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[56]  J. Q. Brown,et al.  Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans , 2020, medRxiv.

[57]  R. McIntyre,et al.  Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series , 2020, Journal of Thrombosis and Haemostasis.

[58]  Yongsheng Li,et al.  Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19 , 2020, American journal of respiratory and critical care medicine.

[59]  D. McGonagle,et al.  The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease , 2020, Autoimmunity Reviews.

[60]  J. Thachil,et al.  The versatile heparin in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[61]  Weidong Wu,et al.  Virology, Epidemiology, Pathogenesis, and Control of COVID-19 , 2020, Viruses.

[62]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[63]  Y. Li,et al.  Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 , 2020, QJM : monthly journal of the Association of Physicians.

[64]  J. Turnbull,et al.  The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding , 2020, bioRxiv.

[65]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[66]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[67]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[68]  C. Wiedermann.  Anticoagulant therapy for septic coagulopathy and disseminated intravascular coagulation: where do KyberSept and SCARLET leave us? , 2020, Acute medicine & surgery.

[69]  J. Thachil,et al.  The progression from coagulopathy to disseminated intravascular coagulation in representative underlying diseases. , 2019, Thrombosis research.

[70]  K. Yamakawa,et al.  Recombinant Human Soluble Thrombomodulin in Sepsis-Induced Coagulopathy: An Updated Systematic Review and Meta-Analysis , 2018, Thrombosis and Haemostasis.

[71]  J. Simpkins,et al.  Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome , 2018, The International journal of neuroscience.

[72]  M. Matthay,et al.  Meta-Analysis of Preclinical Studies of Fibrinolytic Therapy for Acute Lung Injury , 2018, Front. Immunol..

[73]  Jen-Ren Wang,et al.  Macrophage migration inhibitory factor is critical for dengue NS1-induced endothelial glycocalyx degradation and hyperpermeability , 2018, PLoS pathogens.

[74]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[75]  J. Devlin,et al.  Polypharmacy and Delirium in Critically Ill Older Adults: Recognition and Prevention. , 2017, Clinics in geriatric medicine.

[76]  J. Shatzel,et al.  Syndromes of Thrombotic Microangiopathy. , 2017, The Medical clinics of North America.

[77]  S. Orfanos,et al.  Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation , 2016, Respiration.

[78]  J. Giri,et al.  Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. , 2014, JAMA.

[79]  M. Sebbane,et al.  Fibrinolysis for patients with intermediate-risk pulmonary embolism. , 2014, The New England journal of medicine.

[80]  D. Prough,et al.  Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome , 2014, The journal of trauma and acute care surgery.

[81]  B. Gage,et al.  Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients , 2013, Thrombosis and Haemostasis.

[82]  G. Bernard,et al.  A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation* , 2013, Critical care medicine.

[83]  T. van der Poll,et al.  Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome , 2013, Journal of thrombosis and haemostasis : JTH.

[84]  M. Norouzian,et al.  Aloe vera gel and thyroid hormone cream may improve wound healing in Wistar rats , 2012, Anatomy & cell biology.

[85]  K. Jones,et al.  Management of Plastic Bronchitis With Topical Tissue-type Plasminogen Activator , 2012, Pediatrics.

[86]  Andrew Rhodes,et al.  Drotrecogin alfa (activated) in adults with septic shock. , 2012, The New England journal of medicine.

[87]  P. Tuinman,et al.  Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations , 2012, Critical Care.

[88]  G. Ford,et al.  Pharmacokinetics of alteplase in the treatment of ischaemic stroke , 2012, Expert opinion on drug metabolism & toxicology.

[89]  T. van der Poll,et al.  Nebulized Anticoagulants Limit Coagulopathy But Not Inflammation in Pseudomonas aeruginosa-Induced Pneumonia in Rats , 2011, Shock.

[90]  S. Opal,et al.  Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. , 2011, American journal of respiratory and critical care medicine.

[91]  T. van der Poll,et al.  Coagulation biomarkers in critically ill patients. , 2011, Critical care clinics.

[92]  N. Maniatis,et al.  Inhaled activated protein C protects mice from ventilator-induced lung injury , 2010, Critical care.

[93]  J. Ornato,et al.  2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[94]  A. Higure,et al.  Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia , 2009, Critical care medicine.

[95]  V. Kuzkov,et al.  Inhaled aerosolised recombinant human activated protein C ameliorates endotoxin-induced lung injury in anaesthetised sheep , 2009, Critical care.

[96]  N. Anas,et al.  Fontan Patient with Plastic Bronchitis Treated Successfully Using Aerosolized Tissue Plasminogen Activator: A Case Report and Review of the Literature , 2009, Pediatric Cardiology.

[97]  N. Aoki,et al.  Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial , 2007, Journal of thrombosis and haemostasis : JTH.

[98]  P. Reitsma,et al.  Inhalation of activated protein C inhibits endotoxin‐induced pulmonary inflammation in mice independent of neutrophil recruitment , 2006, British journal of pharmacology.

[99]  L. Ware.  Pathophysiology of acute lung injury and the acute respiratory distress syndrome. , 2006, Seminars in respiratory and critical care medicine.

[100]  C. Roussos,et al.  Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. , 2006, Vascular pharmacology.

[101]  Lippincott Williams Wilkins,et al.  ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[102]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[103]  C. Sprung,et al.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.

[104]  M. Matthay,et al.  Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[105]  E. Abraham,et al.  Urokinase-Type Plasminogen Activator Potentiates Lipopolysaccharide-Induced Neutrophil Activation1 , 2003, The Journal of Immunology.

[106]  D. Pinsky,et al.  Endothelial response to hypoxia: physiologic adaptation and pathologic dysfunction , 2002, Current opinion in critical care.

[107]  E. Martin,et al.  Thrombolytic therapy during cardiopulmonary resuscitation and the role of coagulation activation after cardiac arrest , 2001, Current opinion in critical care.

[108]  H. Harke,et al.  Treatment of Severe Acute Respiratory Distress Syndrome: A Final Report on a Phase I Study , 2001, The American surgeon.

[109]  P. Lyden,et al.  Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model , 2001, Stroke.

[110]  Y. Yamaguchi,et al.  Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. , 2000, American journal of respiratory and critical care medicine.

[111]  P. Bankey,et al.  Inhibition of alveolar neutrophil immigration in endotoxemia is macrophage inflammatory protein 2 independent. , 2000, The Journal of surgical research.

[112]  C. Ruppert,et al.  Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. , 2000, American journal of respiratory and critical care medicine.

[113]  J. Jespersen,et al.  Inhalation/intravenous recombinant tissue plasminogen activator and inhaled heparin in a patient with acute respiratory distress syndrome , 1999 .

[114]  M. Nakashima,et al.  A Novel Recombinant Soluble Human Thrombomodulin, ART‐123, Activates the Protein C Pathway in Healthy Male Volunteers , 1998, Journal of clinical pharmacology.

[115]  H. Harke,et al.  Fibrinolytic agents: a new approach to the treatment of adult respiratory distress syndrome. , 1994, Advances in therapy.

[116]  A. Chang,et al.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. , 1993, The Journal of clinical investigation.

[117]  S. Crabbe,et al.  Acylated Plasminogen‐Streptokinase Activator Complex: A New Approach to Thrombolytic Therapy , 1990, Pharmacotherapy.

[118]  S. Papson,et al.  “Model” , 1981 .

[119]  D. Mahadevan,et al.  To Study The Efficacy of Topical Insulin Vs Conventional Dressing on Wound Healing In Diabetic Foot Ulcers , 2018 .

[120]  A. Artigas,et al.  Anticoagulant therapy in acute respiratory distress syndrome. , 2018, Annals of translational medicine.

[121]  Michael Frankfurter,et al.  Applied Therapeutics The Clinical Use Of Drugs , 2016 .

[122]  H. Lijnen.  Matrix Metalloproteinases and Cellular Fibrinolytic Activity , 2004, Biochemistry (Moscow).

[123]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[124]  K. Stringer,et al.  Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. , 1997, Free radical biology & medicine.

[125]  S. Pizzo,et al.  The effect of plasmin on the subunit structure of human fibrinogen. , 1972, The Journal of biological chemistry.